Northern Capital Management LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 10.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,441 shares of the company’s stock after acquiring an additional 3,090 shares during the period. Johnson & Johnson makes up 1.3% of Northern Capital Management LLC’s holdings, making the stock its 16th biggest holding. Northern Capital Management LLC’s holdings in Johnson & Johnson were worth $4,348,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Pioneer Trust Bank N A OR grew its stake in shares of Johnson & Johnson by 4.5% in the second quarter. Pioneer Trust Bank N A OR now owns 35,818 shares of the company’s stock worth $4,738,000 after acquiring an additional 1,549 shares during the period. Lau Associates LLC lifted its position in shares of Johnson & Johnson by 27.7% during the second quarter. Lau Associates LLC now owns 59,873 shares of the company’s stock valued at $7,921,000 after buying an additional 12,995 shares during the last quarter. Catawba Capital Management VA increased its holdings in shares of Johnson & Johnson by 0.7% during the second quarter. Catawba Capital Management VA now owns 55,710 shares of the company’s stock valued at $7,370,000 after acquiring an additional 390 shares in the last quarter. Robinson Value Management Ltd. increased its holdings in shares of Johnson & Johnson by 0.8% during the second quarter. Robinson Value Management Ltd. now owns 16,144 shares of the company’s stock valued at $2,136,000 after acquiring an additional 135 shares in the last quarter. Finally, Centre Asset Management LLC increased its holdings in Johnson & Johnson by 3.4% in the 2nd quarter. Centre Asset Management LLC now owns 91,540 shares of the company’s stock worth $12,110,000 after buying an additional 2,980 shares during the period. Institutional investors and hedge funds own 65.70% of the company’s stock.
Johnson & Johnson (JNJ) traded down $7.29 during trading hours on Monday, hitting $130.39. The stock had a trading volume of 19,561,229 shares, compared to its average volume of 7,360,000. The firm has a market capitalization of $350,300.00, a price-to-earnings ratio of 334.33, a P/E/G ratio of 2.47 and a beta of 0.74. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 1-year low of $112.62 and a 1-year high of $148.32.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The firm had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same quarter in the prior year, the company posted $1.58 earnings per share. Johnson & Johnson’s quarterly revenue was up 11.5% on a year-over-year basis. analysts expect that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is presently 861.54%.
JNJ has been the topic of a number of analyst reports. Cowen reaffirmed an “outperform” rating and set a $155.00 price objective (up previously from $147.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Jefferies Group raised their price objective on Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a report on Monday, October 16th. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the stock an “outperform” rating in a report on Thursday, October 19th. Barclays raised their price objective on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 18th. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $146.16.
COPYRIGHT VIOLATION NOTICE: “Northern Capital Management LLC Buys 3,090 Shares of Johnson & Johnson (NYSE:JNJ)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/05/johnson-johnson-jnj-holdings-boosted-by-northern-capital-management-llc.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.